Orbimed Advisors LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Orbimed Advisors LLC reported 112 stock positions worth $5.4 billion. Its top holding was Sinovac Biotech (SVA) at 6.2% of the portfolio, followed by Eli Lilly (LLY, 5.2%) and Edgewise Therapeutics (EWTX, 5.0%). Compared with Q4 2023, it opened 20 new positions, sold out of 17, added to 22 and reduced 29. The biggest buy was Janux Therapeutics (JANX, shares +29%) and the biggest sale an exit from Rayzebio (RYZB).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001055951
- Portfolio Value
- $5.4B (Q1 2024)
- SEC Filing
- 0001172661-24-002506 ↗ filed May 15, 2024
Holdings Value
Holdings 112 stocks · $5.4B
| SVA Sinovac Biotech Ltd. | 6.24% | 2,718,735 | $340.0M | No change |
| LLY Eli Lilly & Co. | 5.15% | 360,800 | $280.7M | Reduce -1.3% |
| EWTX Edgewise Therapeutics Inc. | 5.03% | 15,021,721 | $274.0M | Add +3.1% |
| BSX Boston Scientific Corp. | 4.12% | 3,273,000 | $224.2M | Reduce -1.0% |
| ISRG Intuitive Surgical Inc. | 3.61% | 493,100 | $196.8M | Reduce -1.2% |
| BIIB Biogen Inc. | 3.57% | 900,900 | $194.3M | Add +8.9% |
| MRK Merck & Co. Inc. | 3.19% | 1,316,000 | $173.6M | Add +24.7% |
| JANX Janux Therapeutics Inc. | 2.96% | 4,275,553 | $161.0M | Add +28.9% |
| ELVN Enliven Therapeutics Inc. | 2.91% | 8,998,338 | $158.3M | No change |
| THC Tenet Healthcare Corp. | 2.26% | 1,173,300 | $123.3M | Reduce -4.2% |
| BMRN Biomarin Pharmaceutical Inc. | 2.05% | 1,278,500 | $111.7M | Reduce -18.6% |
| ALPN Alpine Immune Sciences Inc. | 1.95% | 2,680,496 | $106.3M | Add +5.7% |
| IRON Disc Medicine Inc. | 1.95% | 1,702,237 | $106.0M | No change |
| SYK Stryker Corp. | 1.77% | 269,000 | $96.3M | No change |
| SPRY Ars Pharmaceuticals Inc. | 1.73% | 9,240,887 | $94.4M | No change |
| SRPT Sarepta Therapeutics Inc. | 1.66% | 697,500 | $90.3M | No change |
| IONS Ionis Pharmaceuticals Inc. | 1.60% | 2,013,033 | $87.3M | Reduce -2.5% |
| ELV Elevance Health Inc. | 1.60% | 168,100 | $87.2M | Add +18.8% |
| XTNT Xtant Medical Holdings Inc. | 1.57% | 73,114,592 | $85.5M | No change |
| EVH Evolent Health Inc. Class A | 1.57% | 2,605,615 | $85.4M | Reduce -5.1% |
| SWTX Springworks Therapeutics Inc. | 1.54% | 1,707,331 | $84.0M | Reduce -47.0% |
| KROS Keros Therapeutics Inc. | 1.54% | 1,268,734 | $84.0M | No change |
| NTRA Natera Inc. | 1.51% | 899,431 | $82.3M | Reduce -5.8% |
| TMO Thermo Fisher Scientific Inc. | 1.41% | 132,000 | $76.7M | Reduce -8.2% |
| APLS Apellis Pharmaceuticals Inc. | 1.40% | 1,297,800 | $76.3M | Add +40.7% |
| PCVX Vaxcyte Inc. | 1.34% | 1,066,131 | $72.8M | Reduce -7.5% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.19% | 1,385,000 | $64.8M | Reduce -16.9% |
| SRRK Scholar Rock Holding Corp. | 1.17% | 3,574,632 | $63.5M | Reduce -15.8% |
| ARGX Argenx SE - ADR | 1.10% | 151,600 | $59.7M | Add +79.2% |
| ICLR Icon PLC | 1.07% | 174,100 | $58.5M | Add +31.7% |
| NBIX Neurocrine Biosciences Inc. | 1.07% | 423,100 | $58.4M | Reduce -18.5% |
| VRNA Verona Pharma Ltd. | 1.00% | 3,398,067 | $54.7M | Reduce -10.1% |
| THRD Third Harmonic Bio Inc. | 1.00% | 5,779,071 | $54.6M | No change |
| AVBP Arrivent Biopharma Inc. | 0.99% | 3,027,328 | $54.1M | New |
| NPCE Neuropace Inc. | 0.97% | 4,003,967 | $52.9M | No change |
| SIBN Si-Bone Inc. | 0.95% | 3,174,521 | $52.0M | Add +38.5% |
| PRLD Prelude Therapeutics Inc. | 0.95% | 10,909,256 | $51.7M | No change |
| VRTX Vertex Pharmaceuticals Inc. | 0.94% | 122,700 | $51.3M | Reduce -30.0% |
| TERN Terns Pharmaceuticals Inc. | 0.92% | 7,619,135 | $50.0M | No change |
| CYTK Cytokinetics Inc. | 0.88% | 682,700 | $47.9M | New |
| APGE Apogee Therapeutics Inc. | 0.88% | 718,901 | $47.8M | Reduce -43.7% |
| CMPX Compass Therapeutics Inc. | 0.81% | 22,362,850 | $44.3M | No change |
| GERN Geron Corp. | 0.78% | 12,893,611 | $42.5M | Add +2558.5% |
| SNDX Syndax Pharmaceuticals Inc. | 0.76% | 1,749,000 | $41.6M | No change |
| QTTB Q32 Bio Inc. | 0.70% | 2,252,987 | $38.4M | New |
| ESPR Esperion Therapeutics Inc. | 0.67% | 13,708,731 | $36.7M | New |
| 0 | 0.66% | 12,048,773 | $36.0M | No change |
| UNH Unitedhealth Group Inc. | 0.64% | 70,000 | $34.6M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 0.56% | 704,842 | $30.5M | Add +31.3% |
| ALXO Alx Oncology Holdings Inc. | 0.56% | 2,717,970 | $30.3M | Reduce -12.2% |
| VERA Vera Therapeutics Inc. | 0.54% | 675,872 | $29.1M | Reduce -55.5% |
| PRAX Praxis Precision Medicines I | 0.52% | 460,512 | $28.1M | New |
| HRTX Heron Therapeutics Inc. | 0.51% | 10,111,550 | $28.0M | Add +70.6% |
| SCPH Scpharmaceuticals Inc. | 0.51% | 5,559,528 | $27.9M | No change |
| SLRN Acelyrin Inc. | 0.50% | 4,001,711 | $27.0M | No change |
| ACET Adicet Bio Inc. | 0.49% | 11,447,140 | $26.9M | Add +37.5% |
| MLYS Mineralys Therapeutics Inc. | 0.48% | 2,021,424 | $26.1M | New |
| RNAM Avidity Biosciences Inc. | 0.47% | 994,100 | $25.4M | New |
| XENE Xenon Pharmaceuticals Inc. | 0.43% | 550,000 | $23.7M | No change |
| REGN Regeneron Pharmaceuticals | 0.40% | 22,800 | $21.9M | Add +68.9% |
| KNTE Kinnate Biopharma Inc. | 0.39% | 8,009,729 | $21.3M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.39% | 739,651 | $21.2M | Add +131.4% |
| NMRA Neumora Therapeutics Inc. | 0.38% | 1,500,000 | $20.6M | No change |
| DYN Dyne Therapeutics Inc. | 0.37% | 708,400 | $20.1M | New |
| MORF Morphic Holding Inc. | 0.36% | 558,500 | $19.7M | Add +104.3% |
| DXCM Dexcom Inc. | 0.36% | 140,300 | $19.5M | Add +91.7% |
| ABCL Abcellera Biologics Inc. | 0.35% | 4,180,768 | $18.9M | No change |
| IMTX Immatics NV | 0.34% | 1,769,708 | $18.6M | Add +14.7% |
| VSTM Verastem Inc. | 0.33% | 1,529,115 | $18.0M | No change |
| AMGN Amgen Inc. | 0.33% | 63,400 | $18.0M | Reduce -50.2% |
| AEROVATE THERAPEUTICS INC | 0.31% | 565,374 | $16.7M | Reduce -25.3% |
| TELA Tela Bio Inc. | 0.30% | 2,835,542 | $16.1M | No change |
| RPTX Repare Therapeutics Inc. | 0.29% | 3,322,488 | $15.6M | No change |
| PASG Passage Bio Inc. | 0.25% | 10,124,576 | $13.7M | No change |
| TYRA Tyra Biosciences Inc. | 0.23% | 768,638 | $12.6M | New |
| CRVS Corvus Pharmaceuticals Inc. | 0.23% | 6,943,654 | $12.4M | No change |
| IVVD Invivyd Inc. | 0.22% | 2,690,300 | $11.9M | Reduce -34.8% |
| PMVP PMV Pharmaceuticals Inc. | 0.20% | 6,475,291 | $11.0M | No change |
| VTYX Ventyx Biosciences Inc. | 0.19% | 1,870,456 | $10.3M | New |
| FATE Fate Therapeutics Inc. | 0.18% | 1,355,352 | $9.9M | Add +156.7% |
| XFOR X4 Pharmaceuticals Inc. | 0.18% | 7,133,515 | $9.9M | No change |
| EXAS Exact Sciences Corp. | 0.18% | 140,400 | $9.7M | New |
| CGEM Cullinan Therapeutics Inc. | 0.16% | 517,606 | $8.8M | Reduce -5.0% |
| NKTX Nkarta Inc. | 0.16% | 800,000 | $8.6M | New |
| LXRX Lexicon Pharmaceuticals Inc. | 0.16% | 3,542,000 | $8.5M | New |
| TXG 10X Genomics Inc. Class A | 0.16% | 225,200 | $8.5M | Add +465.8% |
| TSBX Turnstone Biologics Corp. | 0.15% | 3,099,265 | $8.1M | No change |
| CATX Perspective Therapeutics Inc. | 0.14% | 6,505,800 | $7.7M | New |
| CTMX Cytomx Therapeutics Inc. | 0.14% | 3,544,578 | $7.7M | New |
| FOLD Amicus Therapeutics Inc. | 0.12% | 570,300 | $6.7M | Reduce -29.2% |
| KRYS Krystal Biotech Inc. | 0.12% | 37,166 | $6.6M | Reduce -64.2% |
| VIR Vir Biotechnology Inc. | 0.12% | 640,000 | $6.5M | Add +533.7% |
| APLM Apollomics Inc. | 0.12% | 8,565,456 | $6.4M | No change |
| NSPR Inspiremd Inc. | 0.09% | 2,133,405 | $5.1M | No change |
| IKENA ONCOLOGY INC | 0.09% | 3,539,358 | $5.0M | No change |
| ELEV Elevation Oncology Inc. | 0.09% | 941,275 | $4.8M | Reduce -37.3% |
| PGNY Progyny Inc. | 0.08% | 113,300 | $4.3M | New |
| ORIC Oric Pharmaceuticals Inc. | 0.07% | 287,100 | $3.9M | Reduce -45.1% |
| MIST Milestone Pharmaceuticals Inc. | 0.07% | 2,000,000 | $3.6M | New |
| NXTC Nextcure Inc. | 0.05% | 1,141,200 | $2.5M | Reduce -57.9% |
Options reported separately and not counted above: APLS calls ($8.8M), SIBN calls ($4.1M).
Portfolio Sells Q4 2023 → Q1 2024
| RYZB Rayzebio Inc. | Sold out | 0.00% | −2.95 |
| GRCL Gracell Biotechnologies-ADR | Sold out | 0.00% | −1.87 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −1.70 |
| THRX Theseus Pharmaceuticals Inc. | Sold out | 0.00% | −1.44 |
| RCM R1 RCM Inc. | Sold out | 0.00% | −1.02 |
| HUM Humana Inc. | Sold out | 0.00% | −1.01 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -18.6% | 2.05% | −0.98 |
| SWTX Springworks Therapeutics Inc. | Reduce -47.0% | 1.54% | −0.81 |
| IOVA Iovance Biotherapeutics Inc. | Sold out | 0.00% | −0.77 |
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −0.60 |
| VRNA Verona Pharma Ltd. | Reduce -10.1% | 1.00% | −0.50 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -2.5% | 1.60% | −0.49 |
| VRTX Vertex Pharmaceuticals Inc. | Reduce -30.0% | 0.94% | −0.49 |
| SRRK Scholar Rock Holding Corp. | Reduce -15.8% | 1.17% | −0.43 |
| AMGN Amgen Inc. | Reduce -50.2% | 0.33% | −0.40 |
| ALXO Alx Oncology Holdings Inc. | Reduce -12.2% | 0.56% | −0.37 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −0.30 |
| NBIX Neurocrine Biosciences Inc. | Reduce -18.5% | 1.07% | −0.30 |
| EVH Evolent Health Inc. Class A | Reduce -5.1% | 1.57% | −0.25 |
| QURE Uniqure NV | Sold out | 0.00% | −0.18 |
| GILD Gilead Sciences Inc. | Sold out | 0.00% | −0.16 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −0.14 |
| KRYS Krystal Biotech Inc. | Reduce -64.2% | 0.12% | −0.14 |
| TMO Thermo Fisher Scientific Inc. | Reduce -8.2% | 1.41% | −0.12 |
| PCVX Vaxcyte Inc. | Reduce -7.5% | 1.34% | −0.11 |
| IVVD Invivyd Inc. | Reduce -34.8% | 0.22% | −0.11 |
| FOLD Amicus Therapeutics Inc. | Reduce -29.2% | 0.12% | −0.11 |
| ILMN Illumina Inc. | Sold out | 0.00% | −0.08 |
| AMAM New Ambrx Biopharma Inc. | Sold out | 0.00% | −0.08 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| RCUS Arcus Biosciences Inc. | Sold out | 0.00% | −0.04 |
| AEROVATE THERAPEUTICS INC | Reduce -25.3% | 0.31% | −0.04 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -45.1% | 0.07% | −0.02 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.02 |
| NXTC Nextcure Inc. | Reduce -57.9% | 0.05% | −0.02 |
| LAKESHORE BIOPHARMA CO LTD | Reduce -52.6% | 0.02% | −0.01 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -16.9% | 1.19% | +0.00 |
| CGEM Cullinan Therapeutics Inc. | Reduce -5.0% | 0.16% | +0.05 |
| VERA Vera Therapeutics Inc. | Reduce -55.5% | 0.54% | +0.07 |
| ELEV Elevation Oncology Inc. | Reduce -37.3% | 0.09% | +0.07 |
| APGE Apogee Therapeutics Inc. | Reduce -43.7% | 0.88% | +0.16 |
| ISRG Intuitive Surgical Inc. | Reduce -1.2% | 3.61% | +0.24 |
| BSX Boston Scientific Corp. | Reduce -1.0% | 4.12% | +0.29 |
| NTRA Natera Inc. | Reduce -5.8% | 1.51% | +0.31 |
| THC Tenet Healthcare Corp. | Reduce -4.2% | 2.26% | +0.41 |
| LLY Eli Lilly & Co. | Reduce -1.3% | 5.15% | +0.89 |
Portfolio Buys Q4 2023 → Q1 2024
| JANX Janux Therapeutics Inc. | Add +28.9% | 2.96% | +2.24 |
| EWTX Edgewise Therapeutics Inc. | Add +3.1% | 5.03% | +1.84 |
| AVBP Arrivent Biopharma Inc. | New | 0.99% | +0.99 |
| ALPN Alpine Immune Sciences Inc. | Add +5.7% | 1.95% | +0.98 |
| MRK Merck & Co. Inc. | Add +24.7% | 3.19% | +0.88 |
| CYTK Cytokinetics Inc. | New | 0.88% | +0.88 |
| GERN Geron Corp. | Add +2558.5% | 0.78% | +0.76 |
| QTTB Q32 Bio Inc. | New | 0.70% | +0.70 |
| ESPR Esperion Therapeutics Inc. | New | 0.67% | +0.67 |
| PRAX Praxis Precision Medicines I | New | 0.52% | +0.52 |
| MLYS Mineralys Therapeutics Inc. | New | 0.48% | +0.48 |
| RNAM Avidity Biosciences Inc. | New | 0.47% | +0.47 |
| ARGX Argenx SE - ADR | Add +79.2% | 1.10% | +0.45 |
| DYN Dyne Therapeutics Inc. | New | 0.37% | +0.37 |
| ICLR Icon PLC | Add +31.7% | 1.07% | +0.32 |
| HRTX Heron Therapeutics Inc. | Add +70.6% | 0.51% | +0.31 |
| APLS Apellis Pharmaceuticals Inc. | Add +40.7% | 1.40% | +0.29 |
| ELV Elevance Health Inc. | Add +18.8% | 1.60% | +0.26 |
| TYRA Tyra Biosciences Inc. | New | 0.23% | +0.23 |
| MORF Morphic Holding Inc. | Add +104.3% | 0.36% | +0.20 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +131.4% | 0.39% | +0.19 |
| VTYX Ventyx Biosciences Inc. | New | 0.19% | +0.19 |
| ACET Adicet Bio Inc. | Add +37.5% | 0.49% | +0.18 |
| EXAS Exact Sciences Corp. | New | 0.18% | +0.18 |
| DXCM Dexcom Inc. | Add +91.7% | 0.36% | +0.18 |
| REGN Regeneron Pharmaceuticals | Add +68.9% | 0.40% | +0.17 |
| NKTX Nkarta Inc. | New | 0.16% | +0.16 |
| LXRX Lexicon Pharmaceuticals Inc. | New | 0.16% | +0.16 |
| FATE Fate Therapeutics Inc. | Add +156.7% | 0.18% | +0.14 |
| CATX Perspective Therapeutics Inc. | New | 0.14% | +0.14 |
| CTMX Cytomx Therapeutics Inc. | New | 0.14% | +0.14 |
| TXG 10X Genomics Inc. Class A | Add +465.8% | 0.16% | +0.11 |
| VIR Vir Biotechnology Inc. | Add +533.7% | 0.12% | +0.10 |
| PGNY Progyny Inc. | New | 0.08% | +0.08 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +31.3% | 0.56% | +0.07 |
| MIST Milestone Pharmaceuticals Inc. | New | 0.07% | +0.07 |
| DVAX Dynavax Technologies Corp. | New | 0.03% | +0.03 |
| IMTX Immatics NV | Add +14.7% | 0.34% | +0.02 |
| LYEL Lyell Immunopharma Inc. | New | 0.01% | +0.01 |
| XERS Xeris Biopharma Holdings Inc. | New | 0.00% | +0.00 |
| SIBN Si-Bone Inc. | Add +38.5% | 0.95% | −0.01 |
| BIIB Biogen Inc. | Add +8.9% | 3.57% | −0.72 |
Options Activity Q4 2023 → Q1 2024
| PFE Pfizer Inc. | call | Sold out | 500,000 | $14.4Mbefore exit |
| APLS Apellis Pharmaceuticals Inc. | call | New | 150,000 | $8.8M |
| SIBN Si-Bone Inc. | call | New | 250,000 | $4.1M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 117 | $5.3B | EWTX, ELVN, LLY, MBX, SVA |
| Q1 2026 | 105 | $4.4B | EWTX, ELVN, LLY, SVA, BSX |
| Q4 2025 | 104 | $4.9B | EWTX, LLY, BSX, SVA, EW |
| Q3 2025 | 98 | $4.2B | EWTX, BSX, LLY, SVA, ELVN |
| Q2 2025 | 97 | $4.0B | SVA, BSX, LLY, EWTX, ELVN |
| Q1 2025 | 106 | $4.2B | SVA, EWTX, BSX, LLY, ELVN |
| Q4 2024 | 111 | $4.8B | EWTX, SVA, BSX, LLY, ISRG |
| Q3 2024 | 109 | $5.5B | EWTX, SVA, LLY, BSX, ISRG |
| Q2 2024 | 108 | $5.0B | SVA, LLY, EWTX, BSX, ISRG |
| Q1 2024 | 112 | $5.4B | SVA, LLY, EWTX, BSX, ISRG |